Orexo’s Annual Report for the 2017 fiscal year has been published and can be downloaded on the company’s website, www.orexo.com (investors/reports, presentations and audiocasts).
UPPSALA, Sweden, March 22, 2018 /PRNewswire/ -- Orexo’s Annual Report for the 2017 fiscal year has been published and can be downloaded on the company’s website, www.orexo.com (investors/reports, presentations and audiocasts). This year, a Sustainability Report is included in the Annual Report.
For further information, please contact:
Orexo AB (publ.)
Lena Wange
IR & Communications Manager
Tel: +46-18-780-88-00
E-mail: ir@orexo.comOrexo
About Orexo
Orexo develops improved pharmaceuticals based on innovative drug delivery technologies. The focus is primarily on opioid dependence and pain but the aim is to address therapeutic areas where our competence and technologies can create value. The products are commercialized by Orexo in the US or via selected partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo sells the product Zubsolv®. Total net sales for 2017 amounted to SEK 643.7 million and the number of employees at year-end was 90. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The head office, where research and development is also performed, is situated in Uppsala, Sweden.
